GNF-5

Modify Date: 2024-01-02 11:26:41

GNF-5 Structure
GNF-5 structure
Common Name GNF-5
CAS Number 778277-15-9 Molecular Weight 418.369
Density 1.4±0.1 g/cm3 Boiling Point 612.4±55.0 °C at 760 mmHg
Molecular Formula C20H17F3N4O3 Melting Point N/A
MSDS Chinese USA Flash Point 324.2±31.5 °C
Symbol GHS06
GHS06
Signal Word Danger

 Use of GNF-5


GNF-5, an analogue of GNF-2 with improved pharmacokinetic properties, is a selective non-ATP competitive inhibitor of Bcr-Abl with an IC50 value of 0.22±0.1 uM (Wild type Abl).IC50 Value: 0.22±0.1 uM (Wild type Abl) [1]Target: Abl GNF-5 is a cell-permeable GNF-2 N-hydroxyethyl carboxamide analog that exhibits in vivo efficacy in suppressing the proliferation of Bcr-abl-expressing Ba/F3 (93% and 83% of no-treatment control, respectively, on days 5 and 7 post treatment; 100 mg/kg b.i.d.) and bone marrow cells (~75% of no-treatment control in both WBC counts and spleen weight on day 7 post treatment; 50 mg/kg b.i.d.) in murine xenograft models of leukemia. Similar to GNF-2, GNF-5 exerts its effect via an allosteric mechanism (IC50 = 0.22 M against wild-type Abl) by targeting the myristate-binding pocket near the c-terminus of Abl kinase domain and thereby altering the conformational dynamics of the ATP-binding pocket. GNF-5 is ineffective toward the myristate-binding site mutant E505K and the ATP-binding site 'gatekeeper' mutant T315I.

 Names

Name N-(2-hydroxyethyl)-3-[6-[4-(trifluoromethoxy)anilino]pyrimidin-4-yl]benzamide
Synonym More Synonyms

 GNF-5 Biological Activity

Description GNF-5, an analogue of GNF-2 with improved pharmacokinetic properties, is a selective non-ATP competitive inhibitor of Bcr-Abl with an IC50 value of 0.22±0.1 uM (Wild type Abl).IC50 Value: 0.22±0.1 uM (Wild type Abl) [1]Target: Abl GNF-5 is a cell-permeable GNF-2 N-hydroxyethyl carboxamide analog that exhibits in vivo efficacy in suppressing the proliferation of Bcr-abl-expressing Ba/F3 (93% and 83% of no-treatment control, respectively, on days 5 and 7 post treatment; 100 mg/kg b.i.d.) and bone marrow cells (~75% of no-treatment control in both WBC counts and spleen weight on day 7 post treatment; 50 mg/kg b.i.d.) in murine xenograft models of leukemia. Similar to GNF-2, GNF-5 exerts its effect via an allosteric mechanism (IC50 = 0.22 M against wild-type Abl) by targeting the myristate-binding pocket near the c-terminus of Abl kinase domain and thereby altering the conformational dynamics of the ATP-binding pocket. GNF-5 is ineffective toward the myristate-binding site mutant E505K and the ATP-binding site 'gatekeeper' mutant T315I.
Related Catalog
References

[1]. Zhang J, et al. Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. Nature. 2010 Jan 28;463(7280):501-6.

[2]. Meirson T, et al. Targeting invadopodia-mediated breast cancer metastasis by using ABL kinase inhibitors. Oncotarget. 2018 Apr 24;9(31):22158-22183.

 Chemical & Physical Properties

Density 1.4±0.1 g/cm3
Boiling Point 612.4±55.0 °C at 760 mmHg
Molecular Formula C20H17F3N4O3
Molecular Weight 418.369
Flash Point 324.2±31.5 °C
Exact Mass 418.125275
PSA 99.86000
LogP 3.31
Appearance of Characters white to beige
Vapour Pressure 0.0±1.9 mmHg at 25°C
Index of Refraction 1.600
Storage condition 2-8°C
Water Solubility DMSO: soluble10mg/mL (clear solution)

 Safety Information

Symbol GHS06
GHS06
Signal Word Danger
Hazard Statements H301-H319
Precautionary Statements P301 + P310-P305 + P351 + P338
Hazard Codes T
Risk Phrases 25-36
Safety Phrases 22-45
RIDADR UN 2811 6.1 / PGIII
HS Code 2933599090

 Synthetic Route

~79%

GNF-5 Structure

GNF-5

CAS#:778277-15-9

Literature: Deng, Xianming; Okram, Barun; Ding, Qiang; Zhang, Jianming; Choi, Yongmun; Adrian, Francisco J.; Wojciechowski, Amy; Zhang, Guobao; Che, Jianwei; Bursulaya, Badry; Cowan-Jacob, Sandra W.; Rummel, Gabriele; Sim, Taebo; Gray, Nathanael S. Journal of Medicinal Chemistry, 2010 , vol. 53, # 19 p. 6934 - 6946

 Precursor & DownStream

Precursor  2

DownStream  0

 Customs

HS Code 2933599090
Summary 2933599090. other compounds containing a pyrimidine ring (whether or not hydrogenated) or piperazine ring in the structure. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%

 Synonyms

Benzamide,N-(2-hydroxyethyl)-3-(6-((4-(trifluoromethoxy)phenyl)amino)-4-pyrimidinyl)
QC-4300
Benzamide, N-(2-hydroxyethyl)-3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]-
N-(2-hydroxyethyl)-3-(6-(4-(trifluoromethoxy)phenylamino)pyrimidin-4-yl)benzamide
GNF-5
N-(2-Hydroxyethyl)-3-(6-{[4-(trifluoromethoxy)phenyl]amino}-4-pyrimidinyl)benzamide
UNII-3ZUA56XMQQ